A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
National Cancer Centre, Singapore
Memorial Sloan Kettering Cancer Center
University of Illinois at Chicago
National University Hospital, Singapore
Merck Sharp & Dohme LLC
National University Hospital, Singapore
Fudan University
Salubris Biotherapeutics Inc
OHSU Knight Cancer Institute
University Medical Center Groningen
Zhejiang Cancer Hospital
M.D. Anderson Cancer Center